On September 2, 2026, the domestically developed 'Dishi Lingfeng' microsurgical robot, created by Hangzhou Dessight Biomedical Co. Ltd., successfully completed its first patient enrollment in a registered clinical trial for robotic-assisted lymphaticovenular anastomosis (LVA) at Zhejiang Provincial People's Hospital. Led by Professor Zheng Youmao, the procedure marked China's first registered clinical trial using a surgical robot for super-microsurgery to treat secondary lymphedema. The Dishi Lingfeng system overcomes the limitations of human dexterity with real-time tremor filtering, motion scaling, and micro-wristed instruments capable of micron-level precision, enabling the connection of lymphatic vessels as small as 0.1 to 1 millimeter in diameter. This multi-center trial will generate rigorous clinical evidence to support regulatory approval and demonstrate the safety and effectiveness of robotic-assisted super-microsurgery for lymphedema patients.

This industry news roundup highlights three major pharmaceutical developments: 1) AbbVie's investigational bispecific antibody etentamig achieved positive topline results in the Phase 3 CERVINO trial, meeting dual primary endpoints for relapsed/refractory multiple myeloma; 2) Gan & Lee Pharmaceuticals and Menarini Group reached an exclusive licensing agreement for the long-acting GLP-1 therapy bofanglutide, with a total potential deal value of up to €726 million; and 3) HUTCHMED entered an exclusive licensing agreement with a GSK subsidiary for the KRAS-EGFR antibody-targeted conjugate HMPL-A830, with a total potential deal value of up to $1.295 billion.

Medtronic has announced a strategic investment of approximately $700 million in Chinese surgical-robotics startup Cornerstone Robotics (Kangnuositeng) and secured distribution rights for its Sentire laparoscopic surgical robot in markets outside the U.S. In oncology news, Akeso reported that an interim analysis of overall survival (OS) in its Phase III HARMONi-2 study met the key secondary endpoint with statistical significance. The trial evaluates Akeso's PD-1/VEGF bispecific antibody ivonescimab against pembrolizumab as a first-line treatment for PD-L1-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC).

ApicHope Pharmaceutical Group Co., Ltd. announced that its innovative drug AR882 has successfully met the primary endpoint in a Phase III clinical trial for treating gout with hyperuricemia. This significant milestone positions AR882 as a potential breakthrough therapy for millions of patients facing limited treatment options. The company plans to leverage these positive results to advance discussions with China's National Medical Products Administration for potential marketing authorization.

Biocytogen Pharmaceuticals has signed a non-exclusive license agreement with Qilu Pharmaceutical, granting rights to a single fully human nanobody molecule generated via its proprietary RenNano® platform for use in neuroscience drug development. The deal includes an upfront payment and additional milestone-based payments tied to development, regulatory, and commercialization achievements. Qilu Pharmaceutical will integrate the molecule into its R&D pipeline to explore innovative treatments for nervous system diseases, leveraging Biocytogen's nanobody technology to address the high scientific and translational challenges in neuroscience drug R&D.

Betta Pharmaceuticals has received approval from China's NMPA for ensartinib hydrochloride capsules as a post-surgical adjuvant treatment for ALK-positive Stage IB to IIIB non-small cell lung cancer (NSCLC), marking the drug's third approved indication. Clinical data demonstrated a two-year disease-free survival rate of 86.4% and an 80% reduction in disease recurrence risk compared to the control group. This approval expands treatment options for early-stage ALK-positive NSCLC patients, a subtype that accounts for 3% to 5% of all NSCLC cases and predominantly affects younger patients with less smoking history.

The interim analysis of the HARMONi-2 trial revealed that Akeso's ivonescimab demonstrated superior overall survival compared to pembrolizumab (Keytruda) in first-line PD-L1-positive non-small cell lung cancer. By outperforming the world's top-selling cancer therapy on the most rigorous clinical endpoint, ivonescimab cements the cornerstone status of IO 2.0 bispecific antibodies, transitioning the narrative from 'me-too' substitution to undeniable superiority. This landmark clinical victory has catalyzed a rally in the biotech sector and marks a pivotal shift from theme-based trading to data-driven valuation, prompting investors to fundamentally reassess and upgrade the clinical and commercial value of Chinese innovative drugs on the global stage.

Huadong Medicine announced that its oral small-molecule GLP-1 receptor agonist HDM1002 (conveglipron) has met the primary endpoint in its Phase III trial for weight management in China, with a New Drug Application (NDA) planned for Q4 2026. Alongside parallel development for type 2 diabetes, the company is expanding its comprehensive metabolic pipeline, including the dual-target agonist HDM1005. This milestone marks a significant step in China's rapidly evolving oral weight-loss market, intensifying the competition in commercialization and multi-dimensional clinical value.

Shares of Akeso, Inc. (09926.HK) surged nearly 4% at the open on Wednesday after the company announced that its flagship drug ivonescimab met the key secondary endpoint of overall survival (OS) in the Phase III HARMONi-2 trial. The registrational study compared ivonescimab head-to-head against pembrolizumab (Keytruda) as first-line treatment for PD-L1 positive locally advanced or metastatic non-small cell lung cancer (NSCLC). An independent data monitoring committee confirmed statistically significant and clinically meaningful positive OS results. Classified as a 'tumor immunotherapy 2.0 foundation drug,' ivonescimab has demonstrated the ability to deliver even greater patient benefits beyond pembrolizumab's achievements, positioning it as a potential next-generation cornerstone therapy in cancer immunotherapy.

AIPher, an AI-native drug discovery company, has completed an angel financing round worth hundreds of millions of yuan, led by Xianghe Capital, with participation from LINKX CAPITAL and a well-known industrial fund. The funds will support R&D of its drug foundation models, including DrugCLIP, and PharmAgents, an AI agent engine for drug discovery. Capital will also be used to build a multimodal closed-loop system integrating computational and experimental “dry” and “wet” labs and advance proprietary and partnered drug pipelines. Its leading pipeline has reached the Pre-PCC stage. AIPher’s core technology originates from teams led by Professor Lan Yanyan and Academician Zhang Yaqin at Tsinghua University’s Institute for AI Industry Research. The company aims to use AI to transform drug discovery from tool optimization to full-process decision-making, addressing long development cycles, high costs, and low success rates. No financial advisor was disclosed.